The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy
The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. A...
Gespeichert in:
| Veröffentlicht in: | Georgian medical news 2006-01 (130), p.61 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | rus |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 130 |
| container_start_page | 61 |
| container_title | Georgian medical news |
| container_volume | |
| creator | Katamadze, N A Lartsuliani, K P Begishvili, N N Dundua, Kh V Kiknadze, M P |
| description | The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. According to the total dose of doxorubicin the patients had been divided to three sub-groups: I subgroup -- 232.2+/-5.8 mg/m(2), II subgroup - 388+/-15.3mg/m(2), III subgroup - 533.1+/-13.6 mg/m(2). It had been revealed the dose-depending evolution of cardiotoxic effect of doxorubicin leading to the development of anthracyclic cardiomyopathy. At anthracyclic cardiomyopathy LV undergoes the same structural-functional changes as the idiopathic dilatative cardiomyopathy. The cardiotoxic effect of doxorubicin is revealed already at law summary dose of 232 mg/m(2), at "critical dose" 356-388 mg/m(2) develops diastolic dysfunction of LV with clinical manifestation of heart failure, and by summary dose of 533 mg/m(2) develops anthracyclic dilatative cardiomyopathy with systolic-diastolic dysfunction of LV and with clinical manifestation of the heart failure. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_16510915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16510915</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-e076381f89a2987615b00be5fab39316740cd474b1e1a5cf681160b54971b0b03</originalsourceid><addsrcrecordid>eNo1j8tqwzAURLVoaUKaXyj6AYNuLPmxLOkTAtl4H66kq1rFtowsl_rva5p2NrOY4cC5YVtQcMgEwGHD9tP0KdYoWVQg79gGCgWiBrVlQ9MSd4RpjsSD4waj9djxSH2w1Pnhg48xGJomjok_he8QZ-2NH7hp10tqKeK4cBws99aHEVPrDbe-w4TJf9EVGPrld1ru2a3DbqL9X-9Y8_LcHN-y0_n1_fh4ykYlVUaiLPIKXFXjoa7KApQWQpNyqPM6h6KUwlhZSg0EqIxbraAQWsm6BC20yHfs4YodZ92TvYzR9xiXy793_gNGhlWG</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Katamadze, N A ; Lartsuliani, K P ; Begishvili, N N ; Dundua, Kh V ; Kiknadze, M P</creator><creatorcontrib>Katamadze, N A ; Lartsuliani, K P ; Begishvili, N N ; Dundua, Kh V ; Kiknadze, M P</creatorcontrib><description>The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. According to the total dose of doxorubicin the patients had been divided to three sub-groups: I subgroup -- 232.2+/-5.8 mg/m(2), II subgroup - 388+/-15.3mg/m(2), III subgroup - 533.1+/-13.6 mg/m(2). It had been revealed the dose-depending evolution of cardiotoxic effect of doxorubicin leading to the development of anthracyclic cardiomyopathy. At anthracyclic cardiomyopathy LV undergoes the same structural-functional changes as the idiopathic dilatative cardiomyopathy. The cardiotoxic effect of doxorubicin is revealed already at law summary dose of 232 mg/m(2), at "critical dose" 356-388 mg/m(2) develops diastolic dysfunction of LV with clinical manifestation of heart failure, and by summary dose of 533 mg/m(2) develops anthracyclic dilatative cardiomyopathy with systolic-diastolic dysfunction of LV and with clinical manifestation of the heart failure.</description><identifier>ISSN: 1512-0112</identifier><identifier>PMID: 16510915</identifier><language>rus</language><publisher>Georgia (Republic)</publisher><subject>Adult ; Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - adverse effects ; Antibiotics, Antineoplastic - therapeutic use ; Cardiomyopathy, Dilated - chemically induced ; Cardiomyopathy, Dilated - physiopathology ; Disease Progression ; Dose-Response Relationship, Drug ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Doxorubicin - therapeutic use ; Female ; Hematologic Neoplasms - drug therapy ; Humans ; Male ; Myocardial Contraction - drug effects ; Risk Factors ; Ventricular Remodeling - drug effects ; Ventricular Remodeling - physiology</subject><ispartof>Georgian medical news, 2006-01 (130), p.61</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16510915$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katamadze, N A</creatorcontrib><creatorcontrib>Lartsuliani, K P</creatorcontrib><creatorcontrib>Begishvili, N N</creatorcontrib><creatorcontrib>Dundua, Kh V</creatorcontrib><creatorcontrib>Kiknadze, M P</creatorcontrib><title>The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy</title><title>Georgian medical news</title><addtitle>Georgian Med News</addtitle><description>The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. According to the total dose of doxorubicin the patients had been divided to three sub-groups: I subgroup -- 232.2+/-5.8 mg/m(2), II subgroup - 388+/-15.3mg/m(2), III subgroup - 533.1+/-13.6 mg/m(2). It had been revealed the dose-depending evolution of cardiotoxic effect of doxorubicin leading to the development of anthracyclic cardiomyopathy. At anthracyclic cardiomyopathy LV undergoes the same structural-functional changes as the idiopathic dilatative cardiomyopathy. The cardiotoxic effect of doxorubicin is revealed already at law summary dose of 232 mg/m(2), at "critical dose" 356-388 mg/m(2) develops diastolic dysfunction of LV with clinical manifestation of heart failure, and by summary dose of 533 mg/m(2) develops anthracyclic dilatative cardiomyopathy with systolic-diastolic dysfunction of LV and with clinical manifestation of the heart failure.</description><subject>Adult</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Cardiomyopathy, Dilated - chemically induced</subject><subject>Cardiomyopathy, Dilated - physiopathology</subject><subject>Disease Progression</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Myocardial Contraction - drug effects</subject><subject>Risk Factors</subject><subject>Ventricular Remodeling - drug effects</subject><subject>Ventricular Remodeling - physiology</subject><issn>1512-0112</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tqwzAURLVoaUKaXyj6AYNuLPmxLOkTAtl4H66kq1rFtowsl_rva5p2NrOY4cC5YVtQcMgEwGHD9tP0KdYoWVQg79gGCgWiBrVlQ9MSd4RpjsSD4waj9djxSH2w1Pnhg48xGJomjok_he8QZ-2NH7hp10tqKeK4cBws99aHEVPrDbe-w4TJf9EVGPrld1ru2a3DbqL9X-9Y8_LcHN-y0_n1_fh4ykYlVUaiLPIKXFXjoa7KApQWQpNyqPM6h6KUwlhZSg0EqIxbraAQWsm6BC20yHfs4YodZ92TvYzR9xiXy793_gNGhlWG</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Katamadze, N A</creator><creator>Lartsuliani, K P</creator><creator>Begishvili, N N</creator><creator>Dundua, Kh V</creator><creator>Kiknadze, M P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200601</creationdate><title>The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy</title><author>Katamadze, N A ; Lartsuliani, K P ; Begishvili, N N ; Dundua, Kh V ; Kiknadze, M P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-e076381f89a2987615b00be5fab39316740cd474b1e1a5cf681160b54971b0b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>rus</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Cardiomyopathy, Dilated - chemically induced</topic><topic>Cardiomyopathy, Dilated - physiopathology</topic><topic>Disease Progression</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Myocardial Contraction - drug effects</topic><topic>Risk Factors</topic><topic>Ventricular Remodeling - drug effects</topic><topic>Ventricular Remodeling - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katamadze, N A</creatorcontrib><creatorcontrib>Lartsuliani, K P</creatorcontrib><creatorcontrib>Begishvili, N N</creatorcontrib><creatorcontrib>Dundua, Kh V</creatorcontrib><creatorcontrib>Kiknadze, M P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Georgian medical news</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katamadze, N A</au><au>Lartsuliani, K P</au><au>Begishvili, N N</au><au>Dundua, Kh V</au><au>Kiknadze, M P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy</atitle><jtitle>Georgian medical news</jtitle><addtitle>Georgian Med News</addtitle><date>2006-01</date><risdate>2006</risdate><issue>130</issue><spage>61</spage><pages>61-</pages><issn>1512-0112</issn><abstract>The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. According to the total dose of doxorubicin the patients had been divided to three sub-groups: I subgroup -- 232.2+/-5.8 mg/m(2), II subgroup - 388+/-15.3mg/m(2), III subgroup - 533.1+/-13.6 mg/m(2). It had been revealed the dose-depending evolution of cardiotoxic effect of doxorubicin leading to the development of anthracyclic cardiomyopathy. At anthracyclic cardiomyopathy LV undergoes the same structural-functional changes as the idiopathic dilatative cardiomyopathy. The cardiotoxic effect of doxorubicin is revealed already at law summary dose of 232 mg/m(2), at "critical dose" 356-388 mg/m(2) develops diastolic dysfunction of LV with clinical manifestation of heart failure, and by summary dose of 533 mg/m(2) develops anthracyclic dilatative cardiomyopathy with systolic-diastolic dysfunction of LV and with clinical manifestation of the heart failure.</abstract><cop>Georgia (Republic)</cop><pmid>16510915</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1512-0112 |
| ispartof | Georgian medical news, 2006-01 (130), p.61 |
| issn | 1512-0112 |
| language | rus |
| recordid | cdi_pubmed_primary_16510915 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - therapeutic use Cardiomyopathy, Dilated - chemically induced Cardiomyopathy, Dilated - physiopathology Disease Progression Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - therapeutic use Female Hematologic Neoplasms - drug therapy Humans Male Myocardial Contraction - drug effects Risk Factors Ventricular Remodeling - drug effects Ventricular Remodeling - physiology |
| title | The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T23%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20feature%20of%20cardial%20remodeling%20process%20at%20Doxorubicin%20chemotherapy%20and%20idiopathic%20dilatative%20cardiomyopathy&rft.jtitle=Georgian%20medical%20news&rft.au=Katamadze,%20N%20A&rft.date=2006-01&rft.issue=130&rft.spage=61&rft.pages=61-&rft.issn=1512-0112&rft_id=info:doi/&rft_dat=%3Cpubmed%3E16510915%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16510915&rfr_iscdi=true |